Ac Immune Sa News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ac immune sa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ac Immune Sa Today - Breaking & Trending Today

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024)Andrea Pfeifer, Ph.D., CEO to lead AC Immune-sponsored symposium on alpha-synuclein pathologies Lausanne, Switzerland, February 22, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations highlighting its preci ....

United States , Nuno Mendon , Dymitr Kostrica , Tamara Seredenina , Elpida Tsika , Fabrizio Stocchi , Werner Poewe , Chris Maggos , Emma Fiorini , Marija Vukicevic , Corey Davis , Damien Nevoltris , Guenther Staffler , Gary Waanders , Francesca Capotosti , Andrea Pfeifer , Cohesion Bureau , Md Medical University Of Innsbruck , Phd University San Raffaele Roma , Investor Relations Corporate Communications , International Media , International Conference On Alzheimer , Announces Upcoming Presentations , International Conference , Portugal March , Closing Remarks ,

AC Immune Progress Update on Phase 2 Active Immunotherapy

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer s and Parkinson diseases ABATE Phase 1b/2 AD trial of ACI-24.060. ....

United States , Andrea Pfeifer , Exchange Commission , Securities Exchange , Progress Update , Tain Phase , Securities Act , Securities Exchange Act , Financial Review , Annual Report , Nasdaq Aciu , Ac Immune Sa , Alzheimer S , Parkinson S ,

AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial

AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of ACI-35.030 on cognition and Tau pathology in approximately 500 participants with preclinical Alzheimer’s disease (AD)Anti-pTau active immunotherapy being designed to potentially prevent or reduce cognitive decline could address need of over 315 million people globally1 with preclinical ADAC Immune to receive ....

United States , Corey Davis , Gary Waanders , Eli Lilly , Chris Maggos , Andrea Pfeifer , Head Of Investor Relations Corporate Communications , Alzheimer Disease Neuroimaging Initiative , Us Food Drug Administration , International Media , Alzheimer Disease Cooperative Study , Janssen Pharmaceuticals Inc , Roche Group , Cohesion Bureau , Disease Advances , Janssen Pharmaceuticals , Biologics License Application , Drug Administration , Australian Imaging , Lifestyle Flagship Study , Disease Neuroimaging Initiative , Disease Cooperative Study , Taut Helper , Investor Relations , Ac Immune , Alzheimers Disease ,

AC Immune Announces Pricing of Underwritten Offering of

AC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 – AC Immune SA (Nasdaq: ACIU) (the. ....

United States , New York , Gary Waanders , Chris Maggos , Corey Davis , Hc Wainwright Co , Cohesion Bureau , Leerink Partners , Redmile Group , Swiss Financial Services , Equity Syndicate Prospectus Department , Head Of Investor Relations Corporate Communications , Syndicate Department , International Media , Exchange Commission , Securities Exchange , Announces Pricing , Underwritten Offering , Common Shares , Avidity Partners , Stempoint Capital , Swiss Financial Services Act , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Financial Review ,

AC Immune Announces Pricing of Underwritten Offering of Common Shares

AC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 – AC Immune SA (Nasdaq: ACIU) (the “Company” or “AC Immune”), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it has priced an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per share. The Company expects the gross proceeds from the offering, before deducting the underwriting ....

New York , United States , Gary Waanders , Chris Maggos , Corey Davis , Head Of Investor Relations Corporate Communications , Syndicate Department , Leerink Partners , Cohesion Bureau , Hc Wainwright Co , International Media , Redmile Group , Securities Exchange , Equity Syndicate Prospectus Department , Swiss Financial Services , Exchange Commission , Announces Pricing , Underwritten Offering , Common Shares , Avidity Partners , Stempoint Capital , Swiss Financial Services Act , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Financial Review ,